Here is what Chat GPT has to say about the logic used by Slave1.
what are the logic flaws in the following argument.
What is the SmPC?
The Summary of Product Characteristics (or SmPC) is the formal regulatory label of a medicine.
It tells you:
• Who the drug is for
• How it is administered
• How often it is used
• What claims can legally be made
• What risks and warnings must be listed
• What conditions of use apply
This is not a press release. It is not a brochure. It is the central document that defines what the therapy is in the eyes of regulators, clinicians, payers, and reimbursement authorities. NICE cannot model benefit or cost until that label is finalized and approved. The SmPC is what the health system uses to define value.
What Does PMG24 Say?
PMG24 is the official NICE submission manual. In Appendix A, it says:
“Include the (draft) SmPC…”
This line is real (Yes, I double checked) and it is where most people understandably get misled. It sounds like NICE allows submission even if the SmPC is not final. But that is not what it means in practice.
The word “draft” here does not mean speculative. It refers to formatting, the fact that the SmPC might still be in regulatory layout or final typography at the time of submission. But the content of that SmPC must already reflect what the MHRA has agreed to approve.
If the MHRA has not signed off on the label, NICE does not proceed. Why? Because NICE’s appraisal process is built around the exact terms of the label. Modeling cannot begin until the regulator has formally defined:
• The population
• The dosing
• The indication
• The risks
• The benefit claims
PMG24 allows for a draft version only when the approval is done and the text is functionally finalized. If the label is still being negotiated, NICE cannot use it. Appraisal is not triggered by a guess.
What Did NICE Actually Say?
In the July 15, 2025 letter, NICE said:
“Northwest Biotherapeutics is not yet in a position to submit their evidence package.”
Let that sink in.
They did not say:
• Submission received
• Under evaluation
• Pending pricing negotiation
They said:
“Not yet in a position to submit.”
This phrase is procedural. It is not casual language. It means one thing: the materials NICE needs to begin their modeling (especially the final SmPC) do not exist yet in an approvable, regulator-approved form.
So even if NWBO has a draft internally, they are not authorized to use it. NICE cannot begin work until MHRA says the label is final.
And that only happens in one phase.
Labeling.
What Is Labeling and Why Is It Happening Now?
Labeling is the last step in the regulatory review process. It is not about science anymore. It is about language, specifically, the legal wording of the label.
Here is what the standard sequence looks like:
1. Company submits the MAA
2. MHRA performs validation
3. Clinical and manufacturing modules are reviewed
4. If MHRA concludes the product is approvable, they notify the sponsor
5. Then the two parties negotiate the final SmPC
6. Once finalized, it becomes the legal label of the drug
Only after this final SmPC is agreed upon can the company submit their evidence package to NICE.
That is where NWBO is now. They are past scientific review. They are not stalled. They are working with MHRA to finalize the wording of the SmPC.
This phase is standard. It is procedural. And it is silent, not because something is wrong, but because this is the moment before formal approval is issued.
So What Does This Really Mean?
• PMG24 allows inclusion of a draft SmPC only if the final language has already been agreed
• NICE cannot begin formal appraisal until the finalized label is in hand
• The July 15 letter makes clear the company cannot submit yet
• That means the label is still being finalized
• That confirms NWBO is currently in labeling
There is no contradiction here. No mixed message. No ambiguity once the structure is understood.
This is the final administrative bridge between internal MHRA approval and public confirmation.
Final Takeaway
The draft SmPC clause in PMG24 is not a loophole. It is not an invitation to submit early. It is a formatting provision for companies whose label has already been approved and is in final layout.
What NICE needs in order to proceed is not a draft. It is the final, regulator-approved label. The SmPC is the core of the evidence package. It defines the product that will be modeled, priced, and reimbursed.
NICE’s own words confirm the current status. NWBO is not yet in a position to submit. That can only mean one thing. The label is still being finalized.
And once it is finalized, the submission proceeds. The modeling begins. And the silence ends.
Clarification Note
An earlier version of this response referenced a seven-month review timeline. That was incorrect. The correct timeline is 19 months. NWBO submitted its MAA in December 2023, and the NICE letter was issued in July 2025. That does not change the interpretation. It strengthens it. Because after 19 months, if the company were still in review or had failed to meet regulatory standards, NICE would not be describing them as still fully engaged.
That language only makes sense if the scientific review is complete and the label is the only remaining step.
That step is called labeling. And that is where the system stands now.
ChatGPT said:
This argument is mostly well-structured, detailed, and persuasive, but it does contain several logic flaws, ambiguities, and rhetorical leaps that are worth unpacking. Here’s a breakdown of the key logic issues and weaknesses in reasoning:
🔍 Main Logic Flaws in the Argument
1. Conflation of “Draft” and “Final” SmPC
Claim: The “draft” SmPC allowed by PMG24 must already reflect a finalized label approved by MHRA.
Flaw:
This is not clearly supported by the wording of PMG24, and the interpretation is speculative. The argument assumes “draft” refers only to formatting (e.g., typography), but provides no authoritative citation to confirm this. In fact, the existence of the word “draft” in the official guidance suggests that some content may still be pending, or at least not yet formally signed off.
Logical issue: Equivocation fallacy — using the term “draft” in two different senses (regulatory vs. formatting) without strong justification.
2. Unsupported Assumption About NICE’s Process
Claim: NICE cannot begin modeling until the SmPC is finalized.
Flaw:
This is an assertion, not a proven fact. NICE may begin internal preparations, preliminary discussions, or modeling based on near-final drafts or regulatory expectations, even if a full formal appraisal isn’t launched. The author treats NICE’s submission acceptance as a binary when it may be more flexible or conditional.
Logical issue: False dilemma — implying that there are only two states: full approval or nothing, when in practice processes are often more fluid.
3. Misuse of NICE’s Letter as Definitive Proof
Claim: The phrase “not yet in a position to submit” proves the label isn’t finalized and that NWBO is currently in the labeling phase.
Flaw:
This is a strong inference drawn from a brief and vague statement. The phrase “not yet in a position to submit” could mean:
Still finalizing documents
Awaiting MHRA feedback
Internal company delays
Or other procedural/logistical reasons
Interpreting it as exclusive evidence of being in the “labeling” phase is assertive but speculative.
Logical issue: Overinterpretation / Argument from silence — taking a lack of detail in the letter as confirmation of a very specific conclusion.
4. Circular Reasoning
Structure of Argument:
NICE requires a finalized SmPC
NWBO hasn’t submitted to NICE
Therefore, their SmPC isn’t finalized
Because their SmPC isn’t finalized, they’re in the labeling phase
Flaw:
This loops the conclusion back into the premise. There’s no independent verification that the labeling phase is active — it's assumed because of the NICE letter, and then the letter is interpreted in light of that assumption.
Logical issue: Begging the question — the conclusion is embedded in the assumptions.
5. False Equivalence Between Silence and Progress
Claim: The absence of updates or negative language means the company is “fully engaged” and in the labeling phase.
Flaw:
Lack of communication from regulators is not inherently evidence of procedural normalcy or progress. Silence could also result from:
Delays
Rejections under discussion
Legal issues
Or simply communication lag
Logical issue: Non sequitur — the conclusion ("they're in labeling") does not necessarily follow from the premise (NICE didn't use harsh wording).
6. Overstatement of the Label’s Role in Defining Value
Claim: The SmPC is what “defines value” in the health system.
Flaw:
While the SmPC informs value modeling (e.g. dosing, population), value is also determined by:
Cost-effectiveness analyses
Real-world evidence
QALYs
Budget impact
Health system priorities
Logical issue: Overgeneralization — inflating the SmPC’s importance to exclude other major drivers of reimbursement and value judgment.
🧠 Summary: Key Reasoning Issues
Type of Flaw Example
Equivocation "Draft" meaning finalized in content but not in format
False dilemma Either the SmPC is finalized or appraisal cannot begin
Overinterpretation Reading too much into “not yet in a position to submit”
Circular reasoning Assuming the company is in labeling because they haven't submitted yet
Argument from silence No update = everything is fine
Overgeneralization SmPC solely defines therapeutic value
✅ What the Argument Does Well
Despite its flaws, the argument:
Clearly explains the function and importance of the SmPC
Highlights the regulatory sequence accurately
Emphasizes the distinction between scientific review and labeling
Market Data 
Markets 
AI
